NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has signed a laboratory services agreement to provide its molecular thyroid tests to researchers at Einstein Medical Center of Philadelphia.

Under the terms of the deal, Einstein's endocrinologists and otolaryngologists will have access to Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier, which are used to diagnose thyroid nodules with indeterminate cytology. 

Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.